Cash from Operations (TTM) Chart

View Cash from Operations (TTM) for MDXG.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (TTM) Chart
Start Trial

Historical Cash from Operations (TTM) Data

View and export this data back to 2008. Start Trial.
Date Value
June 30, 2026 46.13M
March 31, 2026 70.58M
December 31, 2025 74.00M
September 30, 2025 68.93M
June 30, 2025 59.22M
March 31, 2025 66.62M
December 31, 2024 66.20M
September 30, 2024 56.57M
June 30, 2024 49.74M
March 31, 2024 35.70M
December 31, 2023 26.78M
September 30, 2023 10.89M
June 30, 2023 -0.938M
March 31, 2023 -11.72M
December 31, 2022 -17.89M
September 30, 2022 -15.50M
June 30, 2022 -10.13M
March 31, 2022 -5.526M
December 31, 2021 -1.982M
September 30, 2021 -9.017M
June 30, 2021 -19.96M
March 31, 2021 -24.66M
December 31, 2020 -30.26M
September 30, 2020 -43.12M
June 30, 2020 -41.66M
Date Value
March 31, 2020 -36.43M
December 31, 2019 -39.41M
September 30, 2019 -14.76M
June 30, 2019 -8.199M
March 31, 2019 10.36M
December 31, 2018 35.80M
September 30, 2018 55.13M
June 30, 2018 69.68M
March 31, 2018 62.48M
December 31, 2017 62.94M
September 30, 2017 58.83M
June 30, 2017 43.68M
March 31, 2017 37.42M
December 31, 2016 25.80M
September 30, 2016 13.40M
June 30, 2016 17.91M
March 31, 2016 13.62M
December 31, 2015 18.81M
September 30, 2015 22.74M
June 30, 2015 24.38M
March 31, 2015 22.62M
December 31, 2014 16.80M
September 30, 2014 9.357M
June 30, 2014 2.136M
March 31, 2014 0.2017M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (TTM) Range, Past 5 Years

View Cash from Operations (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (TTM) Benchmarks

View Cash from Operations (TTM) Benchmarks
Start Trial
Anika Therapeutics, Inc. 5.977M
Perspective Therapeutics, Inc. -93.07M
ABVC BioPharma, Inc. -2.691M
Enovis Corp. 270.10M
Edwards Lifesciences Corp. 1.720B